IP Group sold a $5m stake to incoming shareholder Celltrion as part of a series A round for Iksuda, a spinout of Bath originally called Glythera.

Iksuda Therapeutics, a UK-based antibody drug conjugates developer spun out of University of Bath, has closed a $47m series A round that included a $5m stake sale by commercialisation firm IP Group to an incoming shareholder, biopharmaceutical firm Celltrion. Celltrion co-led the round with Premier Partners, Mirae Asset and the latter’s subsidiaries. IP Group owns…

The rest of this content is only accessible to University Venturing: News, Data, and Events - Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.